Stay updated on SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.

Latest updates to the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedMinor footer and revision-note updates were made: a new Revision: v3.3.3 was added, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page shows a minor version update from Revision: v3.3.1 to Revision: v3.3.2 in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.3.1 is displayed as a page revision update (replacing v3.2.0) in the header/footer area with no changes to study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page removed a government funding and operating status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check85 days agoChange DetectedMinor layout and formatting updates are visible; core study details such as title, criteria, design, and outcomes appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.